Mohamed Elbaiomy

Dr. Mohamed Elbaiomy

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2020 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
MEMohamed Elbaiomy
Mohamed Elbaiomy
TATamer Akl
Tamer Akl
NANadia Atwan
Nadia Atwan
AEAhmed Ali Elsayed
Ahmed Ali Elsayed
MEMaha Elzaafarany
Maha Elzaafarany
SSS. Shamaa
S. Shamaa
Background. Breast tumors are composed of phenotypically diverse groups of cells; however, it is unclear which of these cells contribute to tumor development. Breast cancer management usually targets proliferating cells, but as breast cancer stem cells are slowly cycling, they may escape these targets whenever they are not actively proliferating. This may explain the occurrence of recurrences and failure of the treatment.Aim. To assess the impact of the BCSC expression on progression-free survival (PFS), overall survival (OS), and tumor response in metastatic breast cancer patients and to correlate the BCSC expression with different clinicopathological parameters.Material. This prospective study enrolled 76 de novo metastatic breast cancer patients recruited from the Oncology Center, Mansoura University, Egypt, with a minimum age 31 years and a maximum of 70 years. Pretreatment BCSC markers (CD44 and CD24) were assessed by immunohistochemistry on formalin-fixed paraffin-embedded tumor tissues from a primary or metastatic site. Patients received different lines of treatment, hormonal or chemotherapy, according to their biological subtypes. Anti-Her2 was added for Her2-positive patients.Results. Thirty-three patients (43.4%) were premenopausal and 43 patients (56.6%) were postmenopausal. Bone-only metastasis was seen in 12 patients (15.7%), however, visceral ± bone metastasis was seen in 64 patients (84.3%). BCSC markers (CD44+ve and CD24−ve) were expressed in 32 patients (42.1%), while 44 patients (57.9%) were not expressing BCSC markers. Out of 32 patients expressing BCSC, 22 patients (68%) were premenopausal and 28 patients (87.5%) were with high-grade (GIII) disease. BCSC was significantly presented in triple negative subtype breast cancer as there were 32 patients with the BCSC expression, and out of them, 15 patients (46.9%) had triple negative disease, 10 patients (31.3%) had luminal subtype, and seven patients (21.9%) were Her2-amplified, while there were 44 patients without BCSC expression, and out of them, 30 patients (68.2%) were of the luminal subtype, no patient (20.5%) had triple negative disease, and five patients (11.4%) were Her2-amplified (P 0.006). Twenty-four patients (31.5%) presented with visceral crisis; out of them, 17 patients (70.1%) were expressing BCSC which also denoted more aggressive disease. Seventy-four patients were candidates for the response assessment. BCSC-expressing patients showed poor response compared to non-BCSC (16.1% responsive versus 51.2%, respectively), with a significance relation (P 0.003). The BCSC expression was associated with both significant short PFS (median, 18 months vs. 35 months;P=0.001) and short OS (median, 26 months vs. 43 months;P=0.003). In multivariate analysis; BCSC expression was an independent prognostic factor for poor OS (P=0.055) along with the molecular subtype (P=0.012), Her2 status (P=0.011), and histologic grade (P=0.037).Conclusion. This study further validates the BCSC expression as a poor prognostic biomarker correlated with poor response, short PFS and OS. So, it could be used as a marker for tailoring treatment with different lines of therapies in further studies. The BCSC expression was highly presented in the triple negative subtype which is an aggressive disease that lacks different targets. So, targeting BCSC may carry a hope in future for this group of patients.

1 September 2015 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
SASalah Aref
Salah Aref
EAEl Sayed Kamel Areida
El Sayed Kamel Areida
MAMohamed Fathy Abdel Aaal
Mohamed Fathy Abdel Aaal
OAOla Mohamed Adam
Ola Mohamed Adam
MEMohamed Sabry El-Ghonemy
Mohamed Sabry El-Ghonemy
TZTarek Abou Zeid
Tarek Abou Zeid

1 January 2016 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
SASalah Aref
Salah Aref
NMNadia El Menshawy
Nadia El Menshawy
MEMohamed Sabry El-Ghonemy
Mohamed Sabry El-Ghonemy
TZTarek Abou Zeid
Tarek Abou Zeid
MEMohamed Elbaiomy
Mohamed Elbaiomy

14 October 2022 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
RERania Abd El-Hamid El-Kady
Rania Abd El-Hamid El-Kady
MEMohamed Elbaiomy
Mohamed Elbaiomy
RERasha Mokhtar Elnagar
Rasha Mokhtar Elnagar
Background: A growing body of evidence suggests that ceftazidime/avibactam (CZA) is a potential therapeutic option for carbapenem-resistant Klebsiella pneumoniae (CRKP) infections; however, resistant strains are increasingly emerged worldwide. Herein, we deemed to investigate the susceptibility profile of CRKP isolates from cancer patients to CZA and to identify the underlying resistance mechanisms. Methods: Clinical samples were obtained from adult patients admitted to the Oncology Center of Mansoura University, Mansoura, Egypt. The antibiotic susceptibility pattern of K. pneumoniae isolates to different antibiotics was tested by the modified Kirby Bauer’s disc diffusion method. Minimum inhibitory concentrations of CZA were assessed using broth microdilution method. Screening for carbapenemase-producing strains was achieved by the modified Hodge test. Multiplex polymerase chain reactions (PCRs) were conducted for uncovering of carbapenemase-encoding genes (blaKPC, blaVIM, blaIMP, blaNDM-1, and blaOXA-48), and outer membrane porin genes (ompK35 and ompK36). Results: A total of 12 CZA-resistant isolates were identified out of 47 CRKP isolates (25.5%). The MIC50 and MIC90 of CZA against CRKP were 1 and 64 μg/mL, respectively. Risk factors for CZA resistance included chronic kidney disease, mechanical ventilation, longer length of hospital stay, and ICU admission. The multivariate logistic regression demonstrated that longer length of hospital stay (P=0.03) was the only independent predictor for acquisition of CZA-resistant isolates. The leading mechanism for CZA resistance was sustained by blaKPC (50%), meanwhile 16.7% and 8.3% of the CZA-resistant isolates harbored blaOXA-48 and blaOXA-48/blaNDM-1, respectively. The MBL-encoding genes blaNDM-1 and blaIMP were detected in 16.7% and 8.3% of the isolates, respectively. Absence of both ompK35 and ompK36 was observed in 58.3% of the CZA-resistant isolates. Conclusion: CZA has displayed superior in vitro activity against CRKP isolates in comparison to other antibiotics; however, thorough molecular characterization of resistant strains is highly recommended in future studies to detect and monitor the emergence of further tackling strains.

1 January 2016
Verified
Journal Article
Closed access
ARAyman Rasmy
Ayman Rasmy
WAW Abozeed
W Abozeed
SES Elsamany
S Elsamany
MEMohamed Elbaiomy
Mohamed Elbaiomy
ANA Nashwa
A Nashwa
AAA AlFaraj
A AlFaraj

10 August 2014 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SASalah Aref
Salah Aref
MEMohamed Sabry El-Ghonemy
Mohamed Sabry El-Ghonemy
TATarek Elsayed Abouzeid
Tarek Elsayed Abouzeid
AEAmr Mohamed El-Sabbagh
Amr Mohamed El-Sabbagh
MEMohamed Elbaiomy
Mohamed Elbaiomy